Egypt ranks number 2 in the world in terms of deaths caused by liver cancer. According to the latest report of WHO, in 2020, liver cancer deaths in Egypt accounted for 24,512 or 4.57% of total deaths
Most of the patients do not feel or show the symptoms related to liver cancer at an early stage, but in later stages, the patient starts to feel a loss of appetite, rapid weight loss, nausea, vomiting, abdominal pain, and swelling. Early detection and availability of a wide range of liver cancer therapeutics help in preventing and treating liver cancer. Therefore, the demand for liver cancer therapeutics in Egypt is surging rapidly.
Apart from this, extensive R&D activities going on in biotechnology and medical science are providing trust to the market. Moreover, several technological advancements in cancer therapeutics, such as the introduction of gene therapy and bioartificial liver, are strengthening the market growth. Furthermore, the increasing investments by both private and government sectors to upgrade the healthcare infrastructure in Egypt are opening great growth avenues for the market players. In addition to this, the growing adoption of smartphones and penetration of high-speed internet has allowed the patients to quickly access medical facilities remotely, hence creating a positive outlook for the market. All these aforementioned factors are expected to propel the Egypt liver therapeutics market over the forecast period.
DOWNLOAD FREE SAMPLE REPORT
Market Segmentation
The Egypt liver cancer therapeutics market is segmented by type, by therapy, by end users, competitional landscape, and regional distribution.
Company Profile
Roche Egypt LLC, Bayer Middle East FZE, Eli Lilly and Company (Egypt), Merck Egypt, and Novartis Egypt,
| Attribute | Details |
| Base Year | 2021 |
| Historical Data | 2017 – 2020 |
| Estimated Year | 2022 |
| Forecast Period | 2023 – 2027 |
| Quantitative Units | Revenue in USD Million, volume in units, and CAGR for 2017-2021 and 2022-2027 |
| Report coverage | Revenue forecast, volume forecast, company share, competitive landscape, growth factors, and trends |
| Segments covered | · Type · Therapy · End User |
| Regional scope | Cario, Alexandria, Giza Qalyubia, Port Said Suez, and Rest of Egypt |
| Key companies profiled | Roche Egypt LLC, Bayer Middle East FZE, Eli Lilly and Company (Egypt), Merck Egypt, and Novartis Egypt |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
